CLINICAL TRIAL / NCT06276491

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • Interventional
  • OPEN TO ACCRUAL
  • NCT06276491

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.